Literature DB >> 7459807

Natural history of central nervous system acute leukemia in adults.

D J Stewart, M J Keating, K B McCredie, T L Smith, E Youness, S G Murphy, G P Bodey, E J Freireich.   

Abstract

Central nervous system (CNS) involvement occurred in 45 of 222 (20.3%) leukemic adults achieving bone marrow (BM) complete remission (CR), including 12 of 23 (52%) acute undifferentiated leukemia (AUL), 12 of 32 (39%) lymphoma leukemia, 5 of 26 (19%) acute lymphoblastic leukemia, and 16 of 142 (11%) acute myelogenous leukemia. Risk factors for CNS disease were lactic dehydrogenase (LDH) greater than or equal to 25,000/mm3. AUL morphology, age less than 20 years, and extramedullary involvement were most significant. Pattern of CNS involvement varied with morphology. Survival after CNS relapse depended most on BM status and symptoms. Duration of CNS CR was longest for asymptomatic patients with low CSF cell counts. Also important were duration of first BM CR, ease of achievement of initial BM CR, and leukocyte count (original and at most closely antecedent BM involvement), reflecting the common origin of BM and CNS leukemic cells. Central nervous system relapse generally did not shorten BM CR or survival, although early primary CNS relapse was associated with early BM relapse.

Entities:  

Mesh:

Year:  1981        PMID: 7459807     DOI: 10.1002/1097-0142(19810101)47:1<184::aid-cncr2820470130>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Meningeal metastases: clinical aspects and diagnosis.

Authors:  F Formaglio; A Caraceni
Journal:  Ital J Neurol Sci       Date:  1998-06

Review 2.  Leukemia and the nervous system.

Authors:  Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

3.  Central nervous system involvement at first relapse in patients with acute myeloid leukemia.

Authors:  David Martínez-Cuadrón; Pau Montesinos; Mariluz Pérez-Sirvent; Amparo Avaria; Lourdes Cordón; Rebeca Rodríguez-Veiga; Guillermo Martín; Jaime Sanz; Jesús Martínez; Miguel A Sanz
Journal:  Haematologica       Date:  2011-05-12       Impact factor: 9.941

4.  A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.

Authors:  F Mandelli; M L Vegna; G Avvisati; S Amadori; A Spadea; E Cacciola; N Cantore; A De Laurenzi; C De Rosa; G Fioritoni
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

5.  Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.

Authors:  Jai Grewal; Marlon Saria; Harpreet K Grewal; Santosh Kesari
Journal:  Clin Investig (Lond)       Date:  2011-10

Review 6.  Leukemic and lymphomatous meningitis: incidence, prognosis and treatment.

Authors:  Marc C Chamberlain; Craig Nolan; Lauren E Abrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

7.  Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.

Authors:  Uri Rozovski; Maro Ohanian; Farhad Ravandi; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Jorge Cortes; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2014-11-03

8.  Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.

Authors:  Chezi Ganzel; Judith Manola; Dan Douer; Jacob M Rowe; Hugo F Fernandez; Elisabeth M Paietta; Mark R Litzow; Ju-Whei Lee; Selina M Luger; Hillard M Lazarus; Larry D Cripe; Peter H Wiernik; Martin S Tallman
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

Review 9.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Meningeosis leukaemica in adult acute lymphoblastic leukaemia.

Authors:  N Gökbuget; D Hoelzer
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.